New derivatives for treating TRPM3-mediated disorders
JP2025517512A5Pending Publication Date: 2026-06-03KATHOLIEKE UNIV LEUVEN +1
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- KATHOLIEKE UNIV LEUVEN
- Filing Date
- 2023-05-25
- Publication Date
- 2026-06-03
AI Technical Summary
Technical Problem
Current treatments for TRPM3-mediated disorders such as pain and epilepsy lack effective alternatives with minimal side effects and optimal pharmacokinetic properties.
Method used
Development of a novel class of compounds that act as antagonists of TRPM3, specifically designed to modulate TRPM3-mediated disorders, including pain, epilepsy, and inflammatory hypersensitivity.
Benefits of technology
The compounds effectively prevent or treat TRPM3-mediated disorders with good efficacy, low or no side effects, and improved pharmacokinetic and dynamic properties compared to existing treatments.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2023227696000001 
Figure 2023227696000002 
Figure 2023227696000003
Abstract
The present invention relates to compounds useful for the prevention or treatment of TRPM3-mediated disorders, more particularly disorders selected from pain, epilepsy and inflammatory hypersensitivity. The present invention also relates to a method for the prevention or treatment of said TRPM3-mediated disorders.
Need to check novelty before this filing date? Find Prior Art